Cellectis Inc.

Please stand by. Your program is about to begin. If you need audio assistance during today's program, please press star zero. Good day, everyone, and welcome to today's Selectus full year 2024 earnings conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question anytime by pressing the star, then the one key on your telephone keypad. You may withdraw yourself from the queue by pressing the star 2 key. Please note, today's conference is being recorded. I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Arthur Strill. Please go ahead.

Good morning, and welcome, everyone, to Selectus' fourth quarter and full year 2024 business update and financial results conference calls. Joining me on the call today are Dr. André Choulika, our Chief Executive Officer, and Dr. Adrienne Kilcoyne, our Chief Medical Officer. Yesterday evening, Selectus issued a 6K and press release reporting our financial statements for the 12-month period ended December 31, 2024, and a business update. The report and press release are available on our website at selectus.com. As a reminder, we will make statements regarding selected financial outlook, including the sufficiency of cash to fund operations, in addition to our manufacturing, regulatory, and product development status, as well as product development status of our licensed partners. These forward statements which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20F filed with the Security Exchange Commission, SEC, and the financial report, including the management report, for the year ended on December 31st, 2024, and subsequent filing selected SMICs with the SEC from time to time. I would now like to turn the call over to Andre.

Thank you. Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. 2024 has been an important year for Selectus. On the business development front, we were excited to announce the start of research and development activities for three programs developed under our collaboration and research agreement with AstraZeneca. So far, we announced the start of one program of analogenic CAR-T for amyotological malignancies, one program of analogenic CAR-T for solid tumors, and the first of an in vivo gene therapy for genetic disorder. We're thrilled to grow the strategic collaboration with AstraZeneca, a top leader of the pharmaceutical industry, aimed at shaping the future of our next generation of cell and gene therapies. We're very excited about the huge opportunity this partnership will bring in the months ahead. Additionally, this year, AstraZeneca completed the additional equity investment of $140 million in Selectis. As part of the additional investment, AstraZeneca subscribed for 10 million Class A convertible preferred shares and 18 million Class B convertible preferred shares, in each case at a price of $5 per convertible preferred share. giving effect to the conversion of Class A and Class B preferred shares, and immediately after the closing of the subsequent investment, AstraZeneca would own approximately 44% of the share capital of Selectus and approximately 30% of the voting rights. We also drew down the two last tranches of the finance agreement signed in December 2022, with the European Investment Bank for up to 40 million euros credit facility. We're now confident that our cash runway allows us to fund operations into mid-2027. On the clinical side, we're thrilled to have Dr. Adrian Kilcoyne join us as Selectus Chief Medical Officer. Adrian is a huge leader and a strategic forward-thinking drug developer who's passionate about delivering life-saving therapies to patients. He joined us at a pivotal time as we're progressing in our core clinical programs. 2024 was an exciting year with a grant by the FDA to our ProDoc candidate, QCAR T22, of an orphan drug designation and rare pediatric disease, as well as an orphan drug designation granted by the European Commission for the treatment of relapse or refractory acute lymphoblastic leukemia. These designations represent a step toward developing widely available allogenic product for patient in need. Selectives expect to present the phase one data set and late stage development strategy for UCAR T22 in the third quarter of this year. In the NATALI-01 study evaluating UCAR-T20 by 22 in relapsed or refractory non-Hodgkin lymphoma, SELECTiS continues to focus on the enrollment of patients and expect to present phase one dataset and late-stage development strategy in late 2025. In 2024, SELECTiS innovation team showcased promising CAR-T strategies utilizing pain and gene editing technology to target solid tumors and overcome their immunosuppressive tumor microenvironment. Preclinical data were presented at both AACR Immune Oncology and SITC annual meetings, and two scientific articles were published in Molecular Therapy and Science Advances. We're proud to collaborate with leading scientists in the gene editing field who continuously pushes the boundary of innovation and are committed to cancer patients with unmet medical needs. This year, Selectis will continue to focus its efforts and expenses on advancing its core clinical trial, Bally01 and Natalie01, while building the next generation of genomic medicines to address area of high unmet medical needs within our partnership with AstraZeneca and within our proprietary preclinical pipeline. With that, I would like to turn the call over to Dr. Adrian Kilcoyne, our chief medical officer, who will give you an overview of our clinical trials. Adrian, please go ahead.